Metastatic Gastric Cancer Clinical Trial
Official title:
A Pilot Study of Home Parenteral Nutrition for Malnourished Patients With Unresectable Stage IV Gastric Receiving Salvage Chemotherapy
This survey is a single arm study to assess the effect of home parenteral nutrition on overall survival, cycles of salvage chemotherapy completed, side effects of salvage chemotherapy, quality of life, nutritional status, functional status, inflammatory status and complications of HPN in malnourished unresectable metastatic gastric cancer (mGC) patients in a single medical center. It is expected that about 20 subjects will be recruited during an estimated period of 48 months.
Objectives:
1. Primary Objective:
The primary end points are overall survival and cycles of salvage chemotherapy completed
of malnourished patients in unresectable mGCs
2. Secondary Objectives:
Side effects of salvage chemotherapy, quality of life, nutritional status, performance
status, inflammatory status, safety and complications of HPN. The visit time schedules are at
the time of enrollment before HPN is delivered, and at the beginning of every cycle of
salvage chemotherapy
Patient Selection and Enrollment:
Twenty patients are planed to be enrolled
Drop out The following reasons may consider to withdrawing a patient from the study
1. Intolerance adverse events
2. Patient will exceed defined safety cut-off values e.g. increase of a certain amount of a
laboratory parameter.
3. Violation of study protocol
4. Withdraw of informed consent.
Study duration and dates The study of this protocol is expected to be approximately 24
months, with a subject recruitment period of 18 months (proposed to start in Sep 2014 and end
in Sep 2018). The duration of the study or period of recruitment may vary.
Treatment duration HPN is administered till resolution of malnutrition or till patient dies
.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04618809 -
Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer
|
N/A | |
Recruiting |
NCT02668380 -
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
|
N/A | |
Recruiting |
NCT04358354 -
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
|
Phase 3 | |
Completed |
NCT01099527 -
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00253370 -
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
Recruiting |
NCT02002195 -
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
|
||
Recruiting |
NCT06008925 -
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
Recruiting |
NCT02855788 -
Metronomic Chemotherapy in Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT03154983 -
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04263870 -
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 2 | |
Active, not recruiting |
NCT01359397 -
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04739202 -
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
|
Phase 2 | |
Completed |
NCT03409848 -
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05859477 -
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05955833 -
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
|
Phase 1 | |
Terminated |
NCT01528501 -
Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)
|
Phase 2 | |
Completed |
NCT03751761 -
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT05024812 -
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03614013 -
Resistance to Immunotherapy in Gastric Cancer
|